Deep read

How to choose SAVR vs TAVI in severe aortic stenosis

A structured approach to the SAVR vs TAVI decision in severe AS — from indication to approach, with the ACC/AHA VHD 2020 framework as the organizing principle.

Choosing SAVR or TAVI is not the first question. The first question is whether AVR is indicated at all. Once that is settled, the approach decision — SAVR, transfemoral TAVI, or Heart Team review — integrates age, life expectancy, surgical risk, anatomy, and patient preference.

Key takeaway

Decide the indication first. Decide the approach second. AVR indication is mainly driven by symptoms, AS severity, and LV function. The choice between SAVR and TAVI is a separate decision that combines expected longevity, procedural risk, valve durability, anatomy, and the patient's goals.

Key points

Symptomatic severe AS is the clearest Class I indication for AVR.
Asymptomatic severe AS can still justify AVR when LV function is reduced or high-risk features are present.
Age bands are useful, but they are not the whole decision.
Patients younger than 65 years or with life expectancy over 20 years generally favor SAVR per ACC/AHA 2020.
Patients older than 80 years or with life expectancy under 10 years generally favor transfemoral TAVI if anatomy is suitable.
Patients aged 65–80 years are often in the shared decision zone.
Transfemoral access matters — most of the TAVI risk advantage was established in transfemoral TAVI trials.
In younger patients, valve durability, future coronary access, and lifetime valve strategy are central.

Guideline framework

This article is built around ACC/AHA VHD 2020 (Otto et al., JACC 2021). ESC guidelines differ in specific thresholds and recommendations; where the approaches diverge is noted.

Choosing SAVR or TAVI is not the first question

The first question is: does this patient need AVR at all? Most discussions jump directly to TAVI vs SAVR — but the right sequence is indication first, approach second. Once AVR is clearly indicated, the decision shifts to choosing the best approach for this specific patient. That decision depends on age, life expectancy, surgical risk, anatomy, frailty, coronary access, concomitant procedures, and patient preference.

Step 1: Decide whether AVR is indicated

For severe AS, AVR indication is primarily driven by symptom status and echocardiographic severity. The key entry points are:

Class I indications

Symptomatic severe AS: exertional dyspnea, angina, syncope, heart failure, or reduced exercise tolerance with confirmed severe AS.
Severe AS with LVEF below 50%, even if the patient reports no symptoms.
Severe AS in a patient already undergoing other cardiac surgery.

Common Class IIa situations

Very severe AS (Vmax ≥ 5.0 m/s), especially when surgical risk is low.
Severe AS with an abnormal exercise test — symptoms or a fall in blood pressure.
Severe AS with rapid hemodynamic progression (Vmax increase ≥ 0.3 m/s per year).
Selected asymptomatic severe AS patients with high-risk features when procedural risk is low.

Class IIb situations

Selected low-risk asymptomatic patients with severe AS may be considered for early AVR, especially when there are markers suggesting higher future risk.

Step 2: Decide the approach — SAVR, TAVI, or Heart Team review

Once indication is established, the approach decision integrates surgical risk, anatomical factors, patient characteristics, and institutional experience. ACC/AHA VHD 2020 recommends Heart Team evaluation for most patients with severe AS — not as a default of uncertainty, but as the appropriate process for an inherently multidimensional decision.

The key variables at this stage: How long is the patient expected to live? Can the patient tolerate surgery? Is transfemoral TAVI anatomically feasible? Is there bicuspid anatomy or heavy calcification? Will the patient need CABG, mitral surgery, tricuspid surgery, or aortic surgery at the same time? Will future coronary access matter? What does the patient value most?

Factors that favor TAVI

TAVI becomes more attractive when the expected benefit of a less invasive procedure outweighs the long-term durability concerns.

Age over 80 years: shorter life expectancy reduces the durability argument; open surgery carries a higher physiologic burden.
Life expectancy under 10 years: valve durability concern is less relevant.
High or prohibitive surgical risk: STS predicted mortality ≥ 8%, or clinical factors making open surgery unsafe.
Significant frailty: independently associated with worse SAVR outcomes; TAVI's lower procedural burden is a meaningful advantage.
Suitable transfemoral access: the access route through which TAVI's risk advantage was established in major trials.
No need for concomitant cardiac surgery: no reason to open the chest for additional procedures.
Patient preference for a less invasive approach after informed discussion.

Factors that favor SAVR

SAVR remains highly relevant, especially when lifetime strategy matters.

Age under 65 years with life expectancy over 20 years: TAVI valve durability data beyond 10 years is limited; structural valve deterioration may require reintervention before end of life.
Mechanical valve preference: lifelong anticoagulation is acceptable and avoids structural deterioration entirely.
Bicuspid aortic valve anatomy: higher paravalvular leak rates and technical complexity with TAVI; many centers prefer SAVR in younger patients with bicuspid AS.
Need for concomitant cardiac surgery: coronary revascularization, mitral or tricuspid repair, or aortic surgery required at the same time.
Concern about future coronary access after TAVI: anatomy that would make future coronary catheterization difficult.
Heavy annular or LVOT calcification that increases TAVI risk.
Anatomy unfavorable for standard TAVI.

Why many patients are in the shared decision zone

Many patients do not fall cleanly into a TAVI-only or SAVR-only category. In the major randomized trials — PARTNER 2, SURTAVI, PARTNER 3, Evolut Low Risk — TAVI and SAVR showed equivalent short-term outcomes at low and intermediate surgical risk. Neither procedure was clearly superior across all outcomes over two years. For many patients aged 65–80 years with intermediate risk, the decision cannot be made on outcomes data alone.

For these patients, patient preference, local institutional experience, anatomy, and lifetime strategy all legitimately influence the final choice. Shared decision-making — with informed discussion of durability, reintervention likelihood, anticoagulation, and recovery — is the appropriate model.

Pitfall: using age as the only triage rule

Age helps, but it does not decide the case by itself. A fit 67-year-old with long life expectancy and bicuspid AS may be better served by SAVR. A frail 67-year-old with multiple comorbidities and excellent transfemoral anatomy may reasonably move toward TAVI. The age bands are entry points into the conversation, not the final answer.

Practical summary

Confirm severe AS.
Decide whether AVR is indicated — Class I, IIa, or IIb.
Estimate life expectancy and surgical risk.
Check transfemoral access and valve anatomy.
Identify concomitant surgical needs.
Consider durability, coronary access, and lifetime strategy.
Discuss the case with the Heart Team.
Choose SAVR or TAVI with an informed patient.

Apply this in practice

Apply this framework to your patient in the AS Intervention Navigator.

Open AS Intervention Navigator